ENO1 and ovarian carcinoma: By assessing the T cell repertoire to citrullinated peptides in ovarian cancer patients and healthy donors, it was demonstrated that PBMC from 58% of patients proliferated in response to at least one of the PTM peptides and only 12% to both citrullinated Vim and ENO1 peptides [17].